Show simple item record

Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel

dc.contributor.authorChrisanthar, Ranjannb_NO
dc.contributor.authorKnappskog, Stiannb_NO
dc.contributor.authorLøkkevik, Eriknb_NO
dc.contributor.authorAnker, Gun Birgittanb_NO
dc.contributor.authorØstenstad, Bjørnnb_NO
dc.contributor.authorLundgren, Steinarnb_NO
dc.contributor.authorRisberg, Terjenb_NO
dc.contributor.authorMjaaland, Ingvilnb_NO
dc.contributor.authorSkjønsberg, Gudbrandnb_NO
dc.contributor.authorAas, Turidnb_NO
dc.contributor.authorSchlichting, Ellennb_NO
dc.contributor.authorFjøsne, Hans Erikssønnnb_NO
dc.contributor.authorNysted, Arnenb_NO
dc.contributor.authorLillehaug, Johan R.nb_NO
dc.contributor.authorLønning, Per Eysteinnb_NO
dc.date.accessioned2014-12-19T14:18:30Z
dc.date.available2014-12-19T14:18:30Z
dc.date.created2012-08-22nb_NO
dc.date.issued2011nb_NO
dc.identifier546109nb_NO
dc.identifier.issn1932-6203nb_NO
dc.identifier.urihttp://hdl.handle.net/11250/263530
dc.languageengnb_NO
dc.publisherNorges teknisk-naturvitenskapelige universitet, Det medisinske fakultet, Institutt for kreftforskning og molekylær medisinnb_NO
dc.titlePredictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxelnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.source.pagenumber1-10nb_NO
dc.source.volume6nb_NO
dc.source.journalPLoS ONEnb_NO
dc.source.issue4nb_NO
dc.identifier.doi10.1371/journal.pone.0019249nb_NO
dc.contributor.departmentNorges teknisk-naturvitenskapelige universitet, Det medisinske fakultet, Institutt for kreftforskning og molekylær medisinnb_NO


Files in this item

Thumbnail
Name:
546109_FULLTEXT01.pdf
Size:
579.4Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record